Category: Stock Market

Whitehaven Coal Ltd (ASX: WHC) shares are tumbling today.

Shares in the S&P/ASX 200 Index (ASX: XJO) coal stock closed yesterday trading for $8.39. In early afternoon trade on Friday, shares are changing hands for $7.81 apiece, down 5.7%.

For some context, the ASX 200 is down 0.4% at this same time. But most energy stocks are doing it tougher today, as witnessed by the 2.1% decline in the S&P/ASX 200 Energy Index (ASX: XEJ).

Taking a step back, Whitehaven Coal shares remain up 62.7% over 12 months, smashing the 15.9% one-year returns delivered by the benchmark index. And that’s not including the 10 cents a share in fully-franked dividends the coal miner paid eligible stockholders over this time.

Now, here’s how the company just secured a major liquidity boost.

Whitehaven Coal shares ramping up liquidity

In intraday trade today, Whitehaven announced that it has entered into a new US$600 million (AU$853 million) senior secured syndicated facility with a duration of 4.5 years.

The new facility consists of a US$475 million term loan and a US$125 million revolving credit facility.

The ASX 200 coal stock said it has also received bank credit approvals for an additional US$150 million. Management is maintaining the option to upsize this facility as part of Whitehaven’s current refinancing process.

“The support from banking partners reflects confidence in Whitehaven’s financial discipline, cash flow generation and prudent approach to capital management,” Whitehaven managing director and CEO Paul Flynn said.

The new loans are intended to support Whitehaven Coal shares by increasing the miner’s liquidity position, extending its debt maturity profile, and reducing its funding costs. The miner noted that it will now also have more flexibility to support its operations and capital management objectives.

What did management say?

Commenting on the new funding arrangements intended to support Whitehaven Coal shares over the longer term, Flynn said:

With Whitehaven’s strengthened credit profile and successful integration – and initial improvements – of the Daunia and Blackwater metallurgical coal operations, we are focused on refinancing our acquisition credit facility and establishing a capital structure with more diverse, longer tenor and lower cost debt facilities.

The successful execution of the new senior secured syndicated facility, with a headline rate of around 6%, further strengthens our funding flexibility, extends our maturity profile, materially reduces our funding cost and improves our weighted average cost of capital.

With an eye on Whitehaven Coal stockholders, Flynn concluded:

We look forward to completing the refinancing of the balance of our acquisition credit facility and delivering on our broader financing objectives including delivering value for our shareholders.

The post Buying Whitehaven Coal shares? Here’s how the miner just locked in $853 million in funding appeared first on The Motley Fool Australia.

More reading

• Why KMD, Tamboran Resources, Whitehaven Coal, and WiseTech Global shares are falling today
• These were the best-performing ASX 200 shares in March
• 4 ASX 200 energy shares rated buys
• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

AMP Ltd (ASX: AMP) shares are showing some resilience on Friday, holding modest gains despite market sentiment remaining fragile.

At the time of writing, the AMP share price is up 0.53% to $1.317.

AMP shares are still down almost 30% in 2026, making today’s gain stand out. The broader market is under fresh geopolitical pressure following developments in the Middle East.

Against that backdrop, AMP’s latest update appears to be giving investors enough reason to stay put.

Here’s what the market is focusing on.

New CEO sets out the next phase

Today’s catalyst was AMP’s annual general meeting (AGM) update, which included addresses from Chair Mike Hirst and new CEO Blair Vernon.

The update gave shareholders their first chance to hear directly from Vernon since taking over from Alexis George at the end of March.

His message focused on AMP’s progress across wealth, banking, and platforms, while reinforcing the company’s existing priorities around growth, productivity, and capital discipline.

That broadly lines up with what The Australian had flagged ahead of the meeting. Investor focus was expected to centre on capital returns, executive pay, and whether the simpler business structure can keep supporting earnings momentum.

In addition, the internal appointment may also be helping settle investors.

Vernon has been with AMP since 2009 and most recently served as Chief Financial Officer before stepping into the top job.

Capital returns still in focus

Capital management was also part of Friday’s AGM discussion.

AMP reiterated that its previously announced $150 million on-market share buyback is expected to begin in the coming weeks.

The company also maintained its 4 cents per share full-year dividend guidance, subject to business performance and board approval.

At a share price of $1.317, that still points to a yield a little above 3%, which may be helping the stock hold up on a weaker market day.

The AGM materials also noted that AMP’s limited franking balance makes buybacks the preferred way to return excess capital.

Why the shares may be holding up

Friday’s modest gain may simply reflect how low expectations had already become.

After falling nearly 30% in 2026, AMP went into the AGM with sentiment already subdued, which means even a small update can be enough to support the share price.

There was no major surprise in the release, but the steady AGM update and capital return focus may be enough to support the shares.

The stock is also still trading below AMP’s reported net tangible assets backing of roughly $1.48 per share. This could be helping attract value buyers at current levels.

The post Why this beaten-down ASX financial stock is still finding buyers today appeared first on The Motley Fool Australia.

More reading

• 5 ASX shares I’d buy with $10,000 this week
• AMP jumps on $150 million buyback and CEO handover. Is this beaten-down ASX stock turning a corner?
• Why AMP, Greatland Resources, Minerals 260, and Woodside shares are pushing higher today
• AMP shares charge higher on Monday despite market selloff: What’s going on?
• 5 things to watch on the ASX 200 on Monday

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Telix Pharmaceuticals Ltd (ASX: TLX), Magellan Financial Group Ltd (ASX: MFG), and Fortescue Ltd (ASX: FMG) shares are grabbing financial news headlines today.

Heading into the Friday lunch hour, two of the S&P/ASX 200 Index (ASX: XJO) stocks are outperforming the 0.4% losses posted by the benchmark index at this time, while one is trailing those losses.

So, which blue-chip stocks are catching ASX investor interest today?

Read on!

Fortescue shares dip on green energy news

Turning to Fortescue shares first, shares in the ASX 200 iron ore giant are down 2.1% at the time of writing, trading for $20.11 each.

This morning, the miner reported on a major milestone in its journey to eliminate diesel from large-scale industry.

The company said it is accelerating the delivery of the world’s first industrial, fully integrated green energy grid at a scale “comparable to a city”.

Fortescue noted that diesel fuel is 100% imported and “subject to extreme price volatility, unreliability and hardship”. The company said the industry’s diesel use results in billions of dollars in taxpayer-funded subsidies.

The ASX 200 miner expects to save US$100 million in fossil fuel costs by next year. Once its decarbonisation program is fully complete, the company expects C1 unit costs to come down by at least another US$2 to US$4 per wet metric tonne.

Fortescue shares are up 33.4% in 12 months, not including dividends.

Which brings us to…

Telix shares leap on US FDA acceptance

Telix shares are once more leaping onto investors’ radars today.

Shares in the ASX 200 diagnostic and therapeutic product developer are up 7.3% at the time of writing, swapping hands for $14.63 apiece.

Investors have been bidding up Telix shares after the company announced that the United States Food and Drug Administration has accepted its resubmitted New Drug Application (NDA) for TLX101-Px1, the company’s glioma (brain cancer) imaging agent.

“The FDA’s acceptance of our NDA resubmission is an important milestone for Telix,” Kevin Richardson, CEO Telix Precision Medicine, said.

“We appreciate the FDA’s constructive engagement and look forward to working closely with the Agency to urgently obtain approval and then bring this product to market for the benefit of patients,” Richardson added.

Telix shares are down 44.9% over 12 months.

Magellan shares gain on $1.6 billion merger update

Like Telix and Fortescue shares, Magellan is making headline news today following a major announcement.

Magellan shares are up 1.3% at $9.46 apiece after the ASX 200 funds manager updated the market on its proposed full merger with Barrenjoey Capital Partners.

Magellan said it will acquire all of the remaining shares in Barrenjoey in a merger that values Barrenjoey at $1.62 billion.

Magellan shares are up 30.4% in 12 months, not including dividends.

The post Why Magellan, Telix and Fortescue shares are grabbing headlines on Friday appeared first on The Motley Fool Australia.

More reading

• Should you buy Telix shares after its big US news?
• Fortescue shares ease, but this major update could keep momentum building
• Up 31% in a month, why are Telix shares lifting off again on Friday?
• Magellan Financial Group shares in focus following Barrenjoey merger approval
• Where is the value amongst ASX healthcare shares?

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Harvey Norman Holdings Ltd (ASX: HVN) shares are back under pressure on Friday, extending what has already been a bruising year for the retail giant.

In early afternoon trade, the Harvey Norman share price is down 3.33% to $4.65. Earlier in the session, the stock slipped to $4.625, marking a fresh 52-week low.

That leaves the stock down roughly 33% since the start of 2026, a sharp de-rating for one of the ASX’s best-known retail and dividend names.

The fall has dragged Harvey Norman shares back to late 2024 levels, underlining just how quickly sentiment toward consumer retailers has weakened this year.

So, is the sell-off starting to look overdone?

Selling pressure keeps building

The chart has remained almost one-way for most of 2026.

After starting the year above $7, Harvey Norman shares have steadily trended lower, with each bounce fading into renewed selling. And today’s break to a new 52-week low reinforces that momentum remains weak in the near term.

Part of the pressure appears tied to broader concerns around discretionary retail spending, particularly as higher living costs continue to weigh on household budgets.

The market may also be reassessing Harvey Norman’s valuation after its strong run through 2025. Back then, investors appeared comfortable paying a premium for its property-backed balance sheet, large fully franked dividends, and offshore growth exposure.

Even after the sell-off, Harvey Norman is still trading on a dividend yield above 6% based on the current share price.

Its latest fully-franked 14.5 cent interim dividend is due to be paid on 1 May.

Broker support suggests upside still exists

Despite the weak price action, not everyone has turned cautious on the retailer.

Earlier this month, Bell Potter retained a buy rating on Harvey Norman with a $6.70 price target. Based on the current share price, that implies potential upside of more than 40% from here.

The broker’s positive view appears to rest on a few key pillars. These include the company’s large freehold property portfolio, its diversified earnings mix across Australia and international markets, and ongoing store rollout opportunities offshore.

Those factors may be helping some investors look beyond the short-term retail slowdown.

Foolish Takeaway

Harvey Norman shares are now deep in correction territory, with the stock heavily down this year.

Despite weak momentum, the stock’s property backing, strong yield, and broker upside could keep value investors interested.

Right now, Harvey Norman looks like a stock caught between weak sentiment and a valuation that is starting to look more reasonable.

The post Harvey Norman just hit a 52-week low. Is this beaten-down ASX retailer becoming too cheap to ignore? appeared first on The Motley Fool Australia.

More reading

• 2 of the best ASX dividend shares to buy in April
• Why these ASX shares are rated as buys in April
• Bell Potter says this ASX 200 stock can rise 38% and pay a 6% dividend yield
• 5 things to watch on the ASX 200 on Thursday
• 20 ASX shares with ex-dividend dates next week

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Harvey Norman. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

One of the more counterintuitive ideas I have come across in investing is this. Doing less can often lead to better results.

It does not sound right at first. We are conditioned to think that more effort leads to better outcomes. More research, more trades, more activity.

But when it comes to investing, I believe the opposite is often true.

The temptation to act

Markets are constantly moving. Prices go up, prices go down, and there is never a shortage of headlines telling you why. It creates a natural urge to do something. Buy this. Sell that. Adjust your portfolio.

I have felt that myself.

But over time, I have started to question whether all that activity actually improves returns. In many cases, I think it can do the opposite.

Trading frequently increases the risk of making emotional decisions. It can also lead to higher costs and taxes, which quietly eat into long-term performance.

Letting quality businesses do the work

When I think about the investments I feel most comfortable holding, they tend to be high-quality businesses with clear growth drivers.

Companies like CSL Ltd (ASX: CSL), ResMed Inc (ASX: RMD), or WiseTech Global Ltd (ASX: WTC) are not built to deliver their full value in a year or two.

In my view, they need time. Time to expand into new markets. Time to invest in innovation. Time to grow earnings and, ideally, reward shareholders along the way.

If I am constantly buying and selling, I am effectively interrupting that process.

The hidden power of inaction

What I find interesting is that some of the best investment outcomes tend to come from long holding periods.

Not because the investor made perfect decisions along the way, but because they avoided unnecessary ones.

By staying invested, you allow compounding to take hold. Returns generate returns, and over time that can lead to meaningful wealth creation.

It also removes a lot of the stress that comes with trying to time the market. Instead of worrying about short-term movements, the focus shifts to whether the underlying business is still on track.

When doing nothing is not the right move

Of course, I do not think doing nothing is always the answer.

If the fundamentals of a business change, or if the original investment thesis no longer holds, then it can make sense to reassess.

The key distinction, in my opinion, is between thoughtful decisions and reactive ones. Acting based on long-term reasoning is very different from reacting to short-term noise.

Building a portfolio you can stick with

I think this is where the idea of doing less really becomes practical. If I build a portfolio of businesses or ETFs that I genuinely believe in, it becomes much easier to stay the course.

That might include a mix of high-quality individual shares and broad market ETFs that provide diversification.

The goal, at least for me, is to reach a point where I am not constantly questioning every market move.

Instead, I can let the investments do their job.

Foolish Takeaway

Investing does not have to be complicated to be effective. In fact, I believe some of the best outcomes can come from a simple approach. Buy quality assets, hold them for the long term, and avoid the temptation to overreact.

Doing less does not mean not caring. It means focusing on what actually matters. And over time, I think that can make all the difference.

The post Why I think doing less could make you a better ASX investor appeared first on The Motley Fool Australia.

More reading

• Why is this ASX energy stock plunging today?
• This ASX dividend stock is now paying out more than 9%
• Could these ASX stocks double by the end of 2026?
• Up 635% in one year, guess which ASX energy share is rocketing again on Friday
• Should you buy Telix shares after its big US news?

Motley Fool contributor Grace Alvino has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, ResMed, and WiseTech Global. The Motley Fool Australia has positions in and has recommended ResMed and WiseTech Global. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in Beetaloo Energy Ltd (ASX: BTL) have plunged after the company revealed it had raised $66.3 million in new capital via a discounted share placement to institutional and sophisticated investors.

Skin in the game

The company said in a statement to the ASX on Friday that its directors had also agreed to invest in the capital raise, contributing $430,000 between them.

Existing shareholders would also be able to apply for new shares up to a total value of $5 million, at the raise price of 28 cents.

The company’s shares fell from the previous close of 32 cents on the news to be changing hands for 30 cents, down 13%.

The company said it also had access to a $45 million debt facility, which was earmarked for the refurbishment and construction of the Carpentaria gas plant and associated infrastructure.

Managing Director Alex Underwood said the capital raise put the company in a good position.

This Placement marks a pivotal moment for Beetaloo Energy. The participation by existing and new investors reflects genuine conviction in the potential scale of our Beetaloo Basin acreage and projects in the Northern Territory. The Placement received strong support from a broad range of existing and new shareholders including several Australian and international institutional investors. The Beetaloo Basin represents one of the most significant hydrocarbon opportunities in the world. Recent capital initiatives and commitments by Beetaloo Energy, Tamboran, Formentera Partners, Inpex and Santos will see approximately $1 billion invested in the basin over the next 18 months, representing a significant ramp up in activity. With this raising, combined with the upsized $45 million Midstream Infrastructure Facility (undrawn), we are now fully funded through to first pilot gas sales expected in Q4 2026, a milestone that we believe will be transformational for Beetaloo Energy and for Australia’s domestic gas supply.

The new capital raised would be used for the completion of the Carpentaria gas works, continued flow testing at the Carpentaria-5H well, long-lead items for the future work program, and the acquisition of additional seismic data, among other things.

Shares looking cheap

Canaccord Genuity recently issued a research note on Beetaloo Energy, with a speculative buy recommendation on the stock and a price target of 45 cents.

The analyst team said the company’s assets represented “an increasingly derisked opportunity”.

Canaccord said if Beetaloo’s pilot project proved commercial, “we expect majors to move quickly, with Beetaloo’s strategic foothold and first-mover advantage positioning it as a prime beneficiary of the basin’s potential re-rating”.

Beetaloo Energy was valued at $430.3 million at the close on Thursday.

The post Why is this ASX energy stock plunging today? appeared first on The Motley Fool Australia.

More reading

• This ASX dividend stock is now paying out more than 9%
• Could these ASX stocks double by the end of 2026?
• Up 635% in one year, guess which ASX energy share is rocketing again on Friday
• Should you buy Telix shares after its big US news?
• This ASX gold company is up more than 4% on promising early exploration results

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Atlas Arteria Ltd (ASX: ALX) shares have been on the slide recently, pushing the company’s expected dividend yield well past 9%.

The company’s shares have been trending steadily south since about the time the US launched attacks on Iran in late February. There has been no news from the company to explain the steady drift lower.

Dividend aspiration stated

The good news for shareholders, or shareholders to be, is that the company has signalled its intent to keep dividend payments steady at 40 cents per year.

In releasing its full-year results earlier this year, the company said, “Atlas Arteria continues to target future distributions of at least 40 cents per share, supported by growing free cash flow”.

At the current share price of $4.30, that equates to a hefty 9.3% dividend yield, albeit one which is unfranked.

The dividend is certainly not set in stone, but in releasing the full-year results, the company’s Chief Executive Officer, Hugh Wehby, said they were travelling well.

As he said:

2025 was another positive year for Atlas Arteria. We delivered strong revenue growth and steady traffic performance. We continued to build and optimise our businesses to improve safety and customer experience. This performance supports a 40 cents per share distribution for our investors for 2025, in line with guidance. Our refreshed vision – Partnering to deliver world-class road experiences – sharpens our focus. We invest in high-quality partnerships which strengthen our competitive positions and maximise value across our businesses and portfolio. We’re focused on building a resilient portfolio for the long term. That starts with getting the most out of the businesses we own – through strong performance and by pursuing value accretive growth opportunities, including preparing for upcoming French concession retenders. We’re also actively looking at new opportunities across OECD markets where we see strong fundamentals and the potential to deliver attractive returns for securityholders.

The company’s assets include toll road businesses across France, Germany, and the US.

Shares potentially looking cheap

Brokers following the stock also suggest there could be share price upside as well as a strong dividend yield. Of the 10 analysts surveyed by TradingView, the minimum share price target forecast is $4.31, while the highest comes in at $5.56.

The overall rating is neutral, with five of the 10 analysts giving the stock a hold recommendation.

The toll road operator was valued at $6.23 billion at the close of trade on Thursday afternoon.

The post This ASX dividend stock is now paying out more than 9% appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Thursday
• 6 ASX shares hitting 52-week lows amid today’s market rally
• Is it time to load up on these high-yielding ASX dividend shares?
• 3 ASX dividend shares yielding 9% (or more)
• Why Amplitude Energy, Atlas Arteria, Computershare, and Woodside shares are falling today

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The S&P/ASX 200 Index (ASX: XJO) has rebounded this week as sentiment towards the ongoing conflict in the Middle East is improving. 

Since last Thursday, Australia’s benchmark index has recovered roughly 4%. 

If this momentum continues, there are several notable ASX stocks that could be poised for strong growth. 

Here are five ASX stocks with lofty price targets from brokers. 

WiseTech Global Ltd (ASX: WTC)

WiseTech is a provider of logistics software that aims to improve the world’s supply chains. 

It has suffered along with many tech shares at the hands of artificial intelligence integration/takeover fears. 

This has resulted in a 45% fall year to date. 

However, brokers are anticipating a rebound in the mid-term. 

The team at Blackwattle are confident it will be one of the tech shares to emerge from this bear market. 

Additionally, Morgan Stanley has a buy rating on Wisetech along with a $70 price target. 

From today’s stock price of $37.43, that indicates approximately 87% upside. 

Seek Ltd (ASX: SEK)

Similar AI takeover fears have weighed heavily on Seek shares this year. 

The company behind the well-known online employment marketplace has seen its share price fall nearly 37% in 2026. 

Last month, the team at Citi acknowledged there are some headwinds coming for the company, but they still think it is undervalued.

The broker has a $26 price target on this ASX stock, which indicates an upside of roughly 76% from current levels. 

REA Group Ltd (ASX: REA)

REA Group is an online real estate advertising company that provides property and property-related services on websites and mobile apps across Australia, Asia, and North America.

So far in 2026, its share price has fallen by almost 15% and remains down 35% in the last year. 

Some estimates from brokers place a fair price target of $199 on this ASX stock, indicating an upside of 26%. 

Catalyst Metals Ltd (ASX: CYL)

Catalyst Metals is engaged in the mineral exploration, evaluation, and production of gold.

Like many gold shares, it enjoyed a strong run-up until January this year. 

Since then, it has dropped by more than 30%. 

However, 6 analysts’ forecasts on TradingView have an average one-year price target of $14.10, which is 110% above today’s opening stock price of $6.69. 

Vulcan Energy Resources Ltd (ASX: VUL)

Vulcan Energy is focused on providing lithium with a zero-carbon footprint to European electric vehicle manufacturers.

This ASX stock has fallen by approximately 15% year to date. 

Today, it is changing hands for roughly $3.72 per share. 

However, the average analyst stock price target on TradingView is $7.24, which is 94% above current levels. 

The post Could these ASX stocks double by the end of 2026? appeared first on The Motley Fool Australia.

More reading

• 7 ASX 200 shares just upgraded to strong buy ratings
• 2 high-quality ASX stocks to buy and hold long term
• 3 fantastic ASX shares that could help build long-term wealth
• Why Orora, Select Harvests, Tamboran, and WiseTech shares are sinking today
• How to invest $1,000 per month in ASX shares and build long-term wealth

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor Aaron Bell has positions in WiseTech Global. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended WiseTech Global. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ASX energy share Elixir Energy Ltd (ASX: EXR) is leaping higher today.

Elixir Energy shares closed yesterday trading for 13.5 cents. In morning trade on Friday, shares are swapping hands for 14.7 cents apiece, up 8.9%.

To put today’s performance in some context, the S&P/ASX Small Ordinaries Index (ASX: XSO) is down 0.9% at this same time.

While investors who bought Elixir stock yesterday will certainly be pleased, it’s those forward-looking investors who bought shares a year ago that are likely jumping for joy.

Indeed, 12 months ago, you could have picked up the junior ASX energy share for just 2 cents. Meaning you’d be sitting on a gain of 635% right now.

Or enough to turn an $8,000 investment into $58,800.

In one year.

Now, here’s what’s stoking investor interest again today.

ASX energy share jumps on pipeline progress

Elixir Energy shares are surging after the company announced that it has commenced feasibility work on the Taroom Trough pipeline, located in Queensland.

The ASX energy share and APA Group (ASX: APA) have together agreed to complete the feasibility work to achieve the best means for Elixir’s northern Taroom Trough gas to reach the Wallumbilla Gas Hub (WGH).

Management said the joint feasibility work will support a final concept selection for the best pathway of gas produced from Elixir’s planned Lorelle pilot project to reach the WGH.

The company expects initial capital estimates and scheduling details to be delivered in approximately 12 weeks.

Also potentially offering a boost to the ASX energy share today, Elixir said it expects to produce “a significant quantity of associated condensate/light oil along with the gas” from its notional Lorelle pilot.

The company will conduct a separate path to market and plant study to optimise the sale and transport of these liquid volumes into the Queensland refining market at an unspecified future date.

Are Elixir Energy shares still a good buy today?

After rocketing 635% in 12 months, has the ship sailed on this ASX energy share?

Not according to the investment team at Euroz Hartleys.

In late March, the broker noted, “The Lorelle-3 results represent a key de-risking milestone in demonstrating the commerciality of Elixir’s Taroom Trough acreage.”

According to Euroz Hartleys:

The program mirrors the approach taken by neighbouring Supermajor Shell, which is progressing development directly on trend and is understood to have achieved commercial flow rates from the same reservoir.

The broker has a speculative buy rating on Elixir Energy shares with a price target of 19 cents.

That represents a potential upside of more than 29% from current levels.

The post Up 635% in one year, guess which ASX energy share is rocketing again on Friday appeared first on The Motley Fool Australia.

More reading

• Up 222% in a year, why this ASX energy share is forecast to more than double your money again
• How is this ASX energy share leaping 17% in Monday’s sinking market?

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has positions in and has recommended Apa Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Telix Pharmaceuticals Ltd (ASX: TLX) shares are pushing higher on Friday.

At the time of writing, they are up 4% to $14.17 after a major regulatory update in the United States.

The radiopharmaceuticals company announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted New Drug Application (NDA) for TLX101-Px (Pixclara), which is a potential imaging agent for brain cancer.

So, is this a buying opportunity for investors?

A major milestone, but not the finish line

The US FDA acceptance is a significant step forward for Telix.

According to the company, the regulator has now assigned a PDUFA goal date of 11 September, which sets a clear timeline for a potential approval decision.

This is important because it moves the product further along the regulatory pathway and reduces uncertainty around timing.

However, it is worth noting that acceptance is not approval.

There is still a review process ahead, and while the outlook may be positive, regulatory risk remains. Investors should be mindful that outcomes are not guaranteed.

Strong broker support adds confidence

Despite the risks, brokers appear optimistic about Telix’s outlook.

UBS recently placed a buy rating on the company with a $31.00 price target, suggesting that Telix shares could more than double in value from current levels.

Bell Potter is also positive and highlighted the importance of this regulatory catalyst. Earlier this week, it said:

The major short term catalyst is the regulatory update for TLX101 (Pixclara). The company has re-submitted the NDA and is now awaiting confirmation that the resubmission is accepted for review (which is a virtual certainty) at which time the FDA will also publish a PDUFA date. We expect a review period of 6 to 8 months, hence earliest possible approval is 4Q CY26.

The broker also pointed to broader progress across the pipeline. It adds:

The company continues to make good progress on multiple pipeline products. Short term news flow includes acceptance by the FDA of the resubmitted NDA for Pixclara and the amendment to the IND for TLX591 (prostate cancer Tx). We maintain our Buy rating. FY26 EBITDA is increased by ~US$21m to US$55.3m.

This combination of near-term catalysts and improving earnings expectations is helping support the investment case according to the broker.

So much so, it put a buy rating and $19.00 price target on its shares. This implies potential upside of 34% for investors from current levels.

Should you buy Telix shares?

The FDA acceptance is a meaningful milestone that brings Telix closer to unlocking additional value from its pipeline. Combined with bullish brokers and strong momentum across its broader portfolio, the outlook appears encouraging.

However, investors should remember that regulatory approvals are never guaranteed, and volatility is likely along the way. Nevertheless, this could be a good time to consider a patient investment in the radiopharmaceuticals company.

The post Should you buy Telix shares after its big US news? appeared first on The Motley Fool Australia.

More reading

• Up 31% in a month, why are Telix shares lifting off again on Friday?
• Where is the value amongst ASX healthcare shares?
• Telix Pharmaceuticals: FDA accepts Pixclara NDA
• Top brokers name 3 ASX shares to buy today
• 5 things to watch on the ASX 200 on Wednesday

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.